Virtu Financial LLC Acquires New Position in Kura Oncology, Inc. (NASDAQ:KURA)

Virtu Financial LLC bought a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 15,912 shares of the company’s stock, valued at approximately $139,000.

Several other institutional investors and hedge funds also recently bought and sold shares of KURA. E Fund Management Co. Ltd. acquired a new stake in shares of Kura Oncology during the 4th quarter worth approximately $90,000. Corient Private Wealth LLC acquired a new stake in Kura Oncology during the fourth quarter worth $109,000. Teacher Retirement System of Texas raised its position in Kura Oncology by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock valued at $120,000 after purchasing an additional 2,285 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after purchasing an additional 1,750 shares during the last quarter. Finally, Point72 DIFC Ltd purchased a new position in shares of Kura Oncology during the 3rd quarter worth $146,000.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,729 shares of company stock worth $92,307. Corporate insiders own 5.50% of the company’s stock.

Kura Oncology Stock Performance

Shares of KURA opened at $7.05 on Monday. Kura Oncology, Inc. has a 1 year low of $6.79 and a 1 year high of $23.48. The stock has a market capitalization of $569.32 million, a PE ratio of -2.99 and a beta of 0.85. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The stock has a 50-day simple moving average of $7.82 and a 200-day simple moving average of $11.94.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. On average, analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on KURA shares. StockNews.com raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, March 26th. Wedbush reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. UBS Group cut their target price on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. BTIG Research lowered Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Finally, Scotiabank cut their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.